$259 Million

Adaptimmune Therapeutics plc

Follow-on Offering

Lead Left Bookrunner, June 2020

Adaptimmune Therapeutics plc

Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. Adaptimmune’s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the Company to identify cancer targets, find and genetically engineer T-cell receptors (TCRs) and produce therapeutic candidates (SPEAR Tcells) for administration to patients. The Company has three SPEAR T-cell programs in ongoing clinical trials: ADP-A2M4, ADP-A2AFP and ADP-A2M4CD8. ADP-A2M4 is being explored in multiple indications in multiple ongoing clinical trials, including an ongoing Phase I trial in urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal and gastric cancers, synovial sarcoma and MRCLS. ADP-A2AFP, the Company’s alpha fetoprotein (AFP) product candidate, is in a Phase I trial for the treatment of hepatocellular carcinoma (HCC).